Evidence map›Paper›PMID 34628055›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2022

Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.

Zishuo I Hu, Markku Miettinen, Martha Quezado, Alexandra P Lebensohn, Kenneth Aldape, Maria Agra, Cathy Wagner, Yvonne Mallory, Raffit Hassan, Azam Ghafoor

Open access · greenAbstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
  5. Article
  6. GermlineProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zishuo I HuThoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Markku MiettinenLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland.
Martha QuezadoLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland.
Alexandra P LebensohnGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Kenneth AldapeLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland.
Maria AgraThoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Cathy WagnerThoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Yvonne MalloryThoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Raffit HassanThoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Azam GhafoorThoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Electronic address: azam.ghafoor@nih.gov.
National Cancer Institute · USCenter for Cancer Research · US

Funding

Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic MalignanciesZIABC010816 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HASSAN, RAFFIT · 2009 to 2025
$25.5M
Immunohistochemical and genomic analysis of tumorsZIABC011427 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MIETTINEN, MARKKU · 2012 to 2025
$24.0M
Thoracic and Gastrointestinal Oncology Branch Medical Clinical CoreZIDBC011540 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HASSAN, RAFFIT · 2014 to 2025
$17.7M
Development and validation of a predictor of meningioma recurrenceZIABC011847 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALDAPE, KENNETH · 2018 to 2025
$5.9M
Intramural NIH HHS ZID BC011540
6 · The paper itself

Abstract

BAP1 is a tumor suppressor gene implicated in DNA repair and cell growth. Individuals with germline BAP1 mutations are at a significantly increased risk for developing many different cancers including malignant mesothelioma, uveal melanomas, cutaneous melanomas and renal clear cell carcinomas. Meningiomas with absent BAP1 expression have been reported to be more aggressive and present often with rhabdoid features. Here, we report the co-occurrence of pleural mesotheliomas and meningiomas in patients with germline BAP1 mutations. We describe the cancer history, family pedigrees, clinical management, and outcomes of four BAP1 germline mutation carrier families with a history of malignant mesothelioma and meningioma.

Indexed as

Lung NeoplasmsMelanomaMeningeal NeoplasmsMeningiomaMesotheliomaMesothelioma, MalignantGenetic Predisposition to DiseaseGerm-Line MutationHumansTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1GermlineMeningiomaMesothelioma

Identifiers

PMID34628055
PMCPMC10512124
OpenAlexW3206770236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.